Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathology--a molecular prognostic approach.

N J Maughan1, P Quirke

  • 1Academic Unit of Pathology, University of Leeds, Leeds LS1 3EX, UK.

British Medical Bulletin
|November 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymph node mapping-based optimal bowel-resection margin and central radicality in colon cancer surgery: an international, prospective, observational cohort study.

ESMO gastrointestinal oncology·2026
Same author

Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.

Translational oncology·2024
Same author

The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application.

ESMO open·2022

Colorectal cancer recurrence leads to many deaths annually. New molecular markers identified through high-throughput technologies in clinical trials can improve patient prognoses and guide personalized colorectal cancer treatments.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Pathology

Background:

  • Colorectal cancer (CRC) causes significant mortality in England and Wales, primarily due to recurrence.
  • Current prognostic markers for CRC are limited to clinicopathological factors.
  • There is a critical need for improved prognostic tools and individualized treatment strategies for CRC patients.

Purpose of the Study:

  • To explore the potential of post-genomic science and high-throughput technologies in understanding CRC biology.
  • To identify novel molecular prognostic and predictive markers for colorectal cancer.
  • To discover new therapeutic targets for colorectal cancer treatment.

Main Methods:

  • Utilizing high-throughput technologies within the framework of large randomized controlled trials.

Related Experiment Videos

  • Applying post-genomic science to investigate the molecular pathology of colorectal cancer.
  • Analyzing clinicopathological data alongside molecular findings.

    • Main Results:

    • High-throughput technologies offer significant opportunities to advance the understanding of colorectal cancer.
    • Potential for identifying new molecular markers that can predict patient outcomes.
    • Discovery of novel targets for therapeutic intervention in colorectal cancer.

    Conclusions:

    • Integrating advanced molecular technologies with clinical trials is essential for progress in colorectal cancer research.
    • New molecular markers hold promise for enhancing prognostic accuracy and personalizing treatment for colorectal cancer patients.
    • Further research into molecular targets could lead to more effective therapies for colorectal cancer.